About GuideTX
GuideTX is a Healthcare company based in Tucker (United States) founded in 2019 by James Dahlman, and was acquired by Beam Therapeutics in February 2021. Technology for DNA and RNA delivery to targets is provided. GuideTX has raised $19.86 million across 4 funding rounds from investors including Beam Therapeutics, GreatPoint Ventures and Biomatics Capital. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include Candel Therapeutics, StrideBio and Genedit; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2019 and based in Tucker, United States, GuideTx operates in the biotechnology sector focused on nucleic acid therapeutics. Delivery systems for DNA and RNA are developed to treat diseases at the genetic level. A flagship lipid nanoparticle is offered for RNA transport to hepatocytes, with FDA approval achieved. A proprietary screening platform is utilized to create nanoparticles for functional delivery into cytoplasm or nucleus.
- Headquarters Tucker, United States
- Founders James Dahlman
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website guidetx.com
- Acquired by Beam Therapeutics (Feb 2021)
- Total Equity Funding$19.86M (USD)
in 4 rounds
- Latest Funding Round$5.86M (USD), Series A
Aug 2020
- InvestorsBeam Therapeutics
& 2 more
- Acquired byBeam Therapeutics
(Feb 2021)
Funding Insights of GuideTX
GuideTX has successfully raised a total of $19.86M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.86 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.86M
- Total Rounds 4
- Last Round Series A — $5.86M
- Investors Count 2
All 4 funding rounds of GuideTX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $5.86M | Series A | – | – | – |
| Jan 2020 | $8M | Series A | – | – | – |
| Apr 2019 | $6M | Series A | – | – | |
| Mar 2019 | Series A | – | – |
3 investors in total: 3 institutional.
Investors in GuideTX
GuideTX has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Beam Therapeutics, GreatPoint Ventures and Biomatics Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors | gpv.com | San Francisco, United States | ||
Early-stage tech and life sciences focused VC firm investing primarily in the US | biomaticscapital.com | Seattle, United States | ||
Developer of gene therapy using CRISPR base editing to treat diseases | 2017 | beamtx.com | Cambridge, United States |
Investor details for GuideTX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GuideTX
2 people are tracked at GuideTX (1 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
James Dahlman | Co-Founder | Leadership |
Andrew Perlman | Director | Board & advisors |
Complete people profiles for GuideTX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GuideTX
4 dated milestones of GuideTX across 2 years, from founding to its latest funding, stage changes and deals.
- Founded GuideTX is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $5.9M.
- Exit Acquired by Beam Therapeutics.
Competitors of GuideTX
GuideTX has 3 listed competitors in our database, 3 of them funded. They include Candel Therapeutics, StrideBio and Genedit.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| candeltx.com | 1999 | United States | $110.3M | 76 | Viral immunotherapies are developed for cancer treatment. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| genedit.com | 2016 | Berkeley, United States | $93.5M | 34 | Genetic medicines are delivered using polymer nanoparticle platforms. |
Detailed competitors of GuideTX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as GuideTX (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GuideTX
GuideTX was founded in 2019.
GuideTX is headquartered in Tucker, United States. It is registered at Tucker, Georgia, United States.
GuideTX is a funded company, having raised a total of $19.86M across 4 funding rounds to date.
Founded in 2019 and based in Tucker, United States, GuideTx operates in the biotechnology sector focused on nucleic acid therapeutics. Delivery systems for DNA and RNA are developed to treat diseases at the genetic level. A flagship lipid nanoparticle is offered for RNA transport to hepatocytes, with FDA approval achieved. A proprietary screening platform is utilized to create nanoparticles for functional delivery into cytoplasm or nucleus.
GuideTX's top competitors include Genedit, Candel Therapeutics and StrideBio.
GuideTX has 3 investors. Key investors include Beam Therapeutics, GreatPoint Ventures, and Biomatics Capital.
Yes. GuideTX was acquired by Beam Therapeutics in February 2021.